High-throughput screening identifies compounds that enhance lentiviral transduction

Gene Therapy

Volumn 21, Issue 12, 2014, Pages 1008-1020

  Johnston, J M ^a,b   Denning, G ^c   Moot, R ^a,b   Whitehead, D ^a   Shields, J ^a   Le Doux, J M ^d   Doering, C B ^a   Spencer, H T ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c Expression Therapeutics LLC ^*  (United States)

^d GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; CAMPTOTHECIN; CD34 ANTIGEN; CD45 ANTIGEN; ETOPOSIDE; FORSKOLIN; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; PACLITAXEL; PHORBOL 13 ACETATE 12 MYRISTATE; RAPAMYCIN; PHORBOLOL MYRISTATE ACETATE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION; HELA CELL LINE; HEMATOPOIETIC STEM CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; K562 CELL LINE; LENTIVIRINAE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVIRUS; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; 3T3 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEK293 CELL LINE; METABOLISM; PROCEDURES; TUMOR CELL LINE; U937 CELL LINE;

ANIMALS; ANTIGENS, CD34; CAMPTOTHECIN; CELL LINE, TUMOR; COLFORSIN; GENETIC THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HEMATOPOIETIC STEM CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LENTIVIRUS; MICE; NIH 3T3 CELLS; SIROLIMUS; TETRADECANOYLPHORBOL ACETATE; TRANSDUCTION, GENETIC; U937 CELLS;

EID: 84927175081     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.80     Document Type: Article

References (37)

1. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326: 818-823
2. Boztug K, Schnmidt M, Schwarzer A, Banerjee PP, D?ez IA, Dewey RA., et al. Stemcell therapy for Wiskott-Aldrich syndrome. N Engl J Med 2010; 363: 1918-1927
3. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F., et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalasseaemia. Nature 2010; 467: 318-322
4. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A., et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010; 2: 36-43
5. Kumar M, Keller B, Makalou N, Sutton RE. Systemic determination of the packaging limit of lentiviral vectors. Hum Gene Ther 2001; 12: 1893-1905
6. Yacoub N, Romanowska M, Haritonova N, Foerster J. Optimized production and concentration of lentiviral vectors containing large inserts. J Gene Med 2007; 9: 579-584
7. Johnston J, Doering CB, Spencer HT. Gene therapy strategies incorporating large transgenes. In: Chunsheng Kang(ed) Gene Therapy - Developments and Future Perspectives. InTech: Croatia, 2011, pp 121-142
8. Radcliffe P, Sion CJM, Wilkes EJ, Custard EJ, Beard GL, Kingsman SM., et al. Analysis of factor VIII mediated suppression of lentiviral vector titres. Gene Therapy 2008; 15: 289-297
9. Lee HJ, Lee YS, Kim HS, Kim YK, Kim JH, Jeon SH., et al. Retronectin enhances lentivirus-mediated gene delivery into hematopoietic progenitor cells. Biologicals 2009; 37: 203-209
10. Davis BM, Humeau L, Slepushkin V, Binder G, Korshalla L, Ni Y., et al. ABC transporter inhibitors that are substrates enhance lentiviral vector transduction into primitive hematopoietic progenitor cells. Blood 2004; 104: 364-373
11. Leuci V, Mesiano G, Gammaitoni L, Cammarata C, Capellero S, Todorovic M., et al. Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34+ cells and T lymphocytes: Implications for the use of low viral doses and large-size vectors. J Biotechnol 2011; 156: 218-226
12. Santoni de Sio FR, Cascio P, Zingale A, Gasparini M, Naldini L. Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is downregulated by cytokines that enhance transduction. Blood 2006; 107: 4257-4265
13. Millington M, Arndt A, Boyd M, Applegate T, Shen S. Towards a clinically relevant transduction protocol for primary human CD34+ hematopoietic stem/progenitor cells. PLoS One 2009; 4: 1-10
14. Groeschel B, Bushman F. Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus. J Virol 2005; 79: 5695-5704
15. Pommier Y, Leo E, Zhang H, Marchand C. DVA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010; 17: 421-433
16. Stahelin RV, Wang J, Blatner NR, Rafter JD, Murray D, Cho W. The Origin of C1A-C2 Interdomain Interactions in Protein Kinase Cα. J Biol Chem 2005; 280: 36452-36463
17. Steinberg SF. Structural basis of protein kinase c isoform function. Phys Rev 2008; 88: 1341-1378
18. Papayannopoulou T, Nakamoto B, Yokochi T, Chait A, Kannagi R. Human erythroleukemia cell line (HEL) undergoes a drastic macrophage-like shift with TPA. Blood 1983; 62: 832-845
19. Doering CB, Gangadharan B, Dukart HZ, Spencer HT. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity. Mol Ther 2007; 15: 1093-1099
20. Wang CX, Sather BD, Wang X, Adair J, Khan I, Singh S Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells. Blood 2014; 124: 913-923
21. Kustikova OS, Schiedlmeier B, Brugman MH, Stahlhut M, Bartels S, Li Z., et al. Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther 2009; 17: 1537-1547
22. Mitchison JM. Growth during the cell cycle. Int Rev Cytol 2003; 226: 165-258
23. Ono Y, Fujii T, Igarashi K, Kuno T, Tanaka C, Kikkawa U., et al. Phorbol ester binding to protein kinase C requires a cysteine-rich zing-finger-like sequence. Proc Natl Acad Sci USA 1989; 86: 4868-4871
24. Kazanietz MG, Bustelo XR, Barbacid M, Kolch W, Mischak H, Wong G., et al. Zinc finger domains and phorbol ester pharmacophore. Analysis of binding to mutated form of protein kinase C zeta and the vav and c-raf proto-oncogene products. J Biol Chem 1994; 269: 11590-11594
25. Kazanietz MG, Barchi JJ Jr, Omichinski JG, Blumberg PM. Low affinity binding of phorbol esters to PKC and its cysteine-rich region in the absence of phospholipids. J Biol Chem 1995; 270: 14679-14684
26. Quest AF, Bardes ES, Bell RM. A phorbol ester binding domain of protein kinase C gamma. Deletion analysis of the Cys2 domain defines a minimal 43-amino acid peptide. J Biol Chem 1994; 269: 2961-2970
27. Ron D, Kazanietz MG. New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J 1999; 13: 1658-1676
28. Kazanietz MG. Eyes wide shut: protein kinase C isozymes are not the only receptors for the phorbol ester tumor promoters. Mol Carcinog 2000; 28: 5-11
29. Tonn T, Herder C, Becker S, Seifried E, Grez M Generation and characterization of human hematopoietic cell lines expressing factor VIII. J Hematother Stem Cell Res 2002; 11: 695-704
30. Warrilow D, Gardner J, Darnell GA, Suhrbier A, Harrich D. HIV type 1 inhibiton by protein kinase C modulatory compounds. AIDS Res Hum Retroviruses. 2006; 22: 854-864
31. Alexaki A, Quiterio SJ, Liu Y, Irish B, Kilareski E, Nonnemacher MR, Wigdahl B PMAinduced differentiation of a bone marrow progenitor cell line activates HIV-1 LTRdriven transcription. DNA Cell Biol 2007; 26: 387-394
32. Strair RK, Schaar D, Goodell L, Aisner J, Chin K, Eid J., et al. Administration of a phorbol ester to patients with hematological malignancies: preliminiary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin Cancer Res 2002; 8: 2512-2518
33. Johnston J, Denning G, Doering CB, Spencer HT. Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A. Gene Therapy 2013; 20: 607-615
34. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-121
35. Gangadharan B, Parker ET, Ide LM, Spencer HT, Doering CB. High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells. Blood 2006; 107: 3859-3864
36. Spencer HT, Denning G, Gautney RE, Dropulic B, Roy AJ, Baranyi L., et al. Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII. Mol Ther 2011; 19: 302-309
37. Doering CB, Healey JF, Parker ET, Barrow RT, Lollar P. High level expression of recombinant porcine coagulation factor VIII. J Biol Chem 2002; 277: 38345-38349